Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
Peroxisome proliferator-activated receptor gamma (PPARgamma) plays a critical albeit poorly defined role in the development and progression of several cancer types including those of the breast, colon, and lung. A PPAR response element (PPRE) reporter assay was utilized to evaluate the selective transactivation of PPARgamma in 10 different cell lines including normal mammary epithelial, breast, lung, and colon cancer cells. Cells were treated with one of four compounds including rosglitizone (Ros), ciglitizone (Cig), 15-deoxy-Delta(12,14)-prostaglandin J2 (PGJ2), or GW 9662 (GW). We observed differences in transactivation between cell lines from different tissue origin, across cell lines from a single tissue type, and selective modulation of PPARgamma within a single cell line by different ligands. Interestingly, GW, a PPARgamma antagonist in adipocytes, enhanced PPRE reporter activation in normal mammary epithelial cells while it had virtually no effect in any of the cancer cell lines tested. Within each cancer type, individual cell lines were found to respond differently to distinct PPARgamma ligands. For instance, Ros, Cig, and PGJ2 were all potent agonist of PPARgamma transactivation in lung adenocarcinoma cell lines while these same ligands had no effect in squamous cell or large cell carcinomas of the lung. Message levels of PPARgamma and retinoid X receptor alpha (RXRalpha) in the individual cell lines were quantitated by real time-polymerase chain reaction (RT-PCR). The ratio of PPARgamma to RXRalpha was predictive of how cells responded to co-treatment of Ros and 9-cis-retinoic acid, an RXRalpha agonist, in two out of three cell lines tested. These data indicate that PPARgamma can be selectively modulated and suggests that it may be used as a therapeutic target for individual tumors.
Allred
Clinton D
CD
Department of Molecular and Biomedical Pharmacology, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Kilgore
Michael W
MW
D000077556:Alitretinoin; D000813:Anilides / Q000494:pharmacology; D001943:Breast Neoplasms / Q000235:genetics*; D018938:Caco-2 Cells; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D019073:HT29 Cells; D006801:Humans; D008024:Ligands; D008175:Lung Neoplasms / Q000235:genetics*; D047495:PPAR gamma / Q000096:biosynthesis / Q000235:genetics*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D047490:Retinoid X Receptor alpha / Q000096:biosynthesis / Q000235:genetics; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D014162:Transfection; D014212:Tretinoin / Q000494:pharmacology
C097240:15-deoxy-delta(12,14)-prostaglandin J2; C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D008024:Ligands; D047495:PPAR gamma; D012333:RNA, Messenger; D047490:Retinoid X Receptor alpha; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077556:Alitretinoin; D014212:Tretinoin; D015230:Prostaglandin D2; C039671:ciglitazone